Fortis Healthcare, a prominent player in India’s healthcare sector, has announced a significant increase in its financial performance for the fourth quarter and full financial year ending March 31, 2026. The company’s consolidated revenues for Q4 FY26 stood at ₹2,365 crore, marking a 17.8% rise compared to the same period last year. Operating EBITDA for the quarter increased by 22.2%, with margins improving to 22.5% from 21.7% in Q4 FY25.
The profit after tax (PAT) for Q4 FY26 surged by 44.2% to ₹271 crore, reflecting robust growth. For the full fiscal year, Fortis Healthcare reported consolidated revenues of ₹9,128 crore, up 17.3% from the previous year. The operating EBITDA for FY26 saw a 31.3% increase, with margins expanding to 22.8% from 20.4% in FY25. The PAT for the year rose by 31.5% to ₹1,064 crore.
The hospital business segment reported a revenue increase of 19% in Q4 FY26, reaching ₹2,023 crore, while the operating EBITDA grew by 19.9% to ₹446 crore. The diagnostics business also showed strong performance, with revenues rising by 11.1% to ₹387 crore and operating EBITDA increasing by 35.9% to ₹85 crore.
Fortis Healthcare’s net debt as of March 31, 2026, was ₹2,334 crore, with a net debt to EBITDA ratio of 1.09x, up from 0.93x the previous year. The increase in debt was primarily attributed to acquisitions, including People Tree Hospital in Bengaluru and Shrimann Hospital in Jalandhar.
The company also highlighted key operational metrics, including a 15% increase in occupied beds for FY26 and significant growth in procedure volumes across specialties like Radiation Therapy and Robotic Surgeries. International patient revenues grew by 18.5% to ₹639 crore, contributing 7.8% to the overall hospital business revenues.
Fortis Healthcare’s CEO, Dr Ashutosh Raghuvanshi, expressed satisfaction with the company’s steady performance and investment in medical equipment and technology. He noted the expansion of the company’s network through acquisitions and brownfield initiatives, adding approximately 500 beds to its network.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).